Wednesday, 31 Dec 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • VIDEO
  • ScienceAlert
  • White
  • man
  • Trumps
  • Watch
  • Season
  • Health
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > BofA Initiates Coverage on Atlassian (TEAM) With Neutral Rating, $200 Price Target
Economy

BofA Initiates Coverage on Atlassian (TEAM) With Neutral Rating, $200 Price Target

Last updated: September 27, 2025 2:15 am
Share
BofA Initiates Coverage on Atlassian (TEAM) With Neutral Rating, 0 Price Target
SHARE

Atlassian Corporation (NASDAQ:TEAM) has emerged as one of the most buzzing AI stocks on Wall Street  this September. Recently, BofA Securities analyst Koji Ikeda has initiated coverage of Atlassian, assigning a Neutral rating with a price target of $200.00.

In a detailed research note to investors, it was highlighted that Atlassian is poised to significantly tap into the $58 billion collaboration and project management market. This optimism stems from its foundational capabilities as a centralized planning tool, a comprehensive platform, and an extensive customer base exceeding 300,000.

Company management has set an ambitious goal of achieving 20% revenue growth through 2027. However, uncertainties loom over this target due to recent strategic decisions, including the cessation of sales support for its Data Center offering and two major acquisitions, which could potentially impact its growth trajectory. Thus, the firm’s current stance is that the risk/reward scenario is balanced until further clarity is obtained.

Atlassian

“We initiate coverage of work management vendor Atlassian (TEAM) with a Neutral rating and $200 PO. We believe Atlassian is positioned to capture share of the $58bn billion collaboration & project management market, given: (1) strong roots as a centralized planning tool; (2) broad platform; and (3) installed base of 300K+ customers. Thus, we are positive on its long-term growth and FCF generation potential. Mgmt believes it can deliver 20%+ total revenue growth through FY27, which looks enticing. However, we regard two recent updates – the expedited end of sales support for its Data Center offering and the notable acquisitions – could obscure the company’s ability to maintain a clear long-term revenue growth profile. Clarity on this matter is crucial, and until then, we find the risk/reward options to be balanced.”

Atlassian Corporation (NASDAQ:TEAM) is a globally recognized software company that specializes in the design, development, licensing, and maintenance of a wide range of software products worldwide.

See also  Arista Networks (ANET) Loses 5.87% on Cutthroat AI Competition

While we recognize the growth potential associated with TEAM as an investment, we must also point out that there are several AI stocks that could present superior upside potential while mitigating downside risk. If you’re interested in discovering an undervalued AI stock that stands to gain significantly from ongoing trends like Trump-era tariffs and the onshoring movement, we invite you to explore our comprehensive report on the best short-term AI stock.

READ NEXT: 10 Must-Watch AI Stocks on Wall Street and 10 AI Stocks on Market Radar

Disclosure: None.

In this rewrite, I have maintained the structure and original HTML tags while ensuring the content is unique and suitable for integration into a WordPress post. The key points from the original article have been preserved to retain the message’s integrity.

TAGGED:AtlassianBofACoverageInitiatesNeutralPriceRatingTargetTeam
Share This Article
Twitter Email Copy Link Print
Previous Article Trump To Shut Down The Government And Raise Prescription Drug Prices 100% On The Same Day
Next Article Trump’s TikTok deal still worries  GOP China hawks — but here’s why they’ll go along Trump’s TikTok deal still worries GOP China hawks — but here’s why they’ll go along
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

My Weekly Reading for November 17, 2024

California’s Electric Vehicle Mandates Pose Challenges for Automakers by Sarah Thompson, The Electric Car Times,…

November 17, 2024

BravoCon to Stream All Panels on Peacock as Full Schedule Unveiled

Peacock is making a bold statement this year by enhancing its coverage of BravoCon. All…

September 30, 2025

Vogue First! Get 24-Hour Exclusive Access to Shop Tory Burch’s Fall 2025 Collection

The Allure of Tory Burch: A Look at the Fall 2025 Collection All products featured…

October 1, 2025

TRAGIC: 27-Year-Old Texas Man Dies Saving Fiancée, Children, and Mother from Raging Floodwaters — “I’m Sorry, I’m Not Going to Make It. I Love Y’all” |

Julian Ryan (Credit: GoFundMe) Tragic Heroism: Julian Ryan's Last Stand Against Nature's Fury In a…

July 7, 2025

Balin Miller Dead: Alaskan Climbing YouTuber Was 23 Years Old

23-year-old climbing influencer, Balin Miller, tragically fell to his death while scaling El Capitan in…

October 4, 2025

You Might Also Like

Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher
Economy

Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher

December 31, 2025
Stefon Diggs’ Talent Makes It Easier for Team to Support Him, Sports Exec Says
Entertainment

Stefon Diggs’ Talent Makes It Easier for Team to Support Him, Sports Exec Says

December 31, 2025
Soybeans Trying to Bounce on Turnaround Tuesday
Economy

Soybeans Trying to Bounce on Turnaround Tuesday

December 31, 2025
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?
Economy

Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?

December 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?